Predict your next investment

CARB-X company logo
Public-Private Partnership
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
carb-x.org

See what CB Insights has to offer

Investments

56

Portfolio Exits

8

Partners & Customers

10

About CARB-X

CARB-X, aka The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, is a public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute, and RTI International.

CARB-X Headquarter Location

765 Commonwealth Ave Suite 1201

Boston, Massachusetts, 02215,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CARB-X Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CARB-X Rank

Research containing CARB-X

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned CARB-X in 1 CB Insights research brief, most recently on Sep 12, 2019.

Latest CARB-X News

CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-Biofilm Technology for Life-Threatening Bacterial Infections

Apr 4, 2022

Supplemental award extends CARB-X collaboration as the Company advances toward first-in-human clinical trials in 2022 April 04, 2022 08:00 AM Eastern Daylight Time COLUMBUS, Ohio--( BUSINESS WIRE )-- Clarametyx Biosciences Inc . (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $3.89 million in option funding. The grant is directed toward accelerated development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia. This supplemental option builds upon the previous funding awards received in 2020 and 2021, and is oriented toward IND-enabling activities such as a GLP toxicity study and Phase 1 material production. Based on the terms of the agreement, Clarametyx will be eligible for one further funding option supporting a first-in-human clinical trial, dependent on achievement of certain developmental milestones and that the product remains a competitive addition to the field. “Advancing to the next option of our agreement with CARB-X helps us further accelerate our efforts toward initiating our first-in-human clinical trials with CMTX-101 later this year,” said David Richards, Chief Executive Officer. “We appreciate the continued support by experts in our field, which reinforces the significant potential of this innovative technology to broadly address challenging bacterial infections.” Clarametyx’s technology continues to generate momentum and awareness as an important complementary approach to antibiotic strategies to effectively resolve challenging biofilm-related infections. The Company’s platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm matrix, rapidly and effectively collapsing the protective shield and rendering the bacteria vulnerable to immune and antibiotic attack. Acknowledgement and disclaimer Research reported in this news release is supported by CARB-X. CARB-X’s funding for this project is sponsored by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from the Wellcome Trust and Germany’s Federal Ministry of Education and Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About CARB-X CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early development antibacterial R&D to address the rising threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services; the Wellcome Trust , a global charity based in the UK working to improve health globally; Germany’s Federal Ministry of Education and Research (BMBF) ; the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC); the Bill & Melinda Gates Foundation , and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the US Department of Health and Human Services. CARB-X is investing up to US$480 million from 2016-2022 to support innovative therapeutics, preventatives, and rapid diagnostics. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list , or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. CARB-X is headquartered at Boston University School of Law. https://carb-x.org/ . Follow us on Twitter @CARB_X. About Clarametyx Biosciences Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia. For more information, visit us on the web or on LinkedIn . Contacts

CARB-X Investments

56 Investments

CARB-X has made 56 investments. Their latest investment was in Clarametyx Biosciences as part of their Grant - II on April 4, 2022.

CBI Logo

CARB-X Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/5/2022

Grant - II

Clarametyx Biosciences

$3.89M

Yes

1

6/10/2021

Grant

Accelerate Diagnostics

$0.58M

Yes

2

6/1/2021

Grant - III

BioVersys

$4.35M

No

4

5/10/2021

Grant - III

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2021

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2022

6/10/2021

6/1/2021

5/10/2021

4/27/2021

Round

Grant - II

Grant

Grant - III

Grant - III

Grant

Company

Clarametyx Biosciences

Accelerate Diagnostics

BioVersys

Subscribe to see more

Subscribe to see more

Amount

$3.89M

$0.58M

$4.35M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

4

10

10

CARB-X Portfolio Exits

8 Portfolio Exits

CARB-X has 8 portfolio exits. Their latest portfolio exit was Specific Diagnostics on April 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/12/2022

Acquired

2

2/12/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/19/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/26/2020

Merger

Subscribe to see more

Subscribe to see more

10

6/12/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/12/2022

2/12/2021

8/19/2020

6/26/2020

6/12/2020

Exit

Acquired

IPO

IPO

Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

CARB-X Partners & Customers

10 Partners and customers

CARB-X has 10 strategic partners and customers. CARB-X recently partnered with T2 Biosystems on November 11, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

11/26/2019

Partner

United States

T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio

The partnership with CARB-X is part of Department for Health and Social Care 's Global Antimicrobial Resistance Innovation Fund .

1

4/2/2019

Vendor

United States

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria : Malin PLC

NEW HAVEN , Conn. , May 07 , 2018 -- Melinta Therapeutics , Inc. , a commercial-stage company discovering , developing and commercializing novel antibiotics to treat serious bacterial infections , today announced that it has entered into a partnership with CARB-X , under which Melinta Therapeutics , Inc. will be awarded up to $ 6.2 million to support the development of the company 's investigational pyrrolocytosine compounds .

1

2/25/2019

Vendor

United States

Kean Institute Joins Global Fight Against Antibiotic-resistant Superbugs.

`` CARB-X is one of the most important avenues of the future to develop new antibiotics , vaccines and other treatments yet to be discovered , '' said Kean President Dawood Farahi , Ph.D. `` Institute for Life Science Entrepreneurship at Kean University 's partnership with CARB-X will allow some of these new ideas to come to fruition . ''

1

2/4/2019

Vendor

Switzerland

Subscribe to see more

Subscribe to see more

10

5/7/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

11/26/2019

4/2/2019

2/25/2019

2/4/2019

5/7/2018

Type

Partner

Vendor

Vendor

Vendor

Partner

Business Partner

Country

United States

United States

United States

Switzerland

United States

News Snippet

T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio

The partnership with CARB-X is part of Department for Health and Social Care 's Global Antimicrobial Resistance Innovation Fund .

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria : Malin PLC

NEW HAVEN , Conn. , May 07 , 2018 -- Melinta Therapeutics , Inc. , a commercial-stage company discovering , developing and commercializing novel antibiotics to treat serious bacterial infections , today announced that it has entered into a partnership with CARB-X , under which Melinta Therapeutics , Inc. will be awarded up to $ 6.2 million to support the development of the company 's investigational pyrrolocytosine compounds .

Kean Institute Joins Global Fight Against Antibiotic-resistant Superbugs.

`` CARB-X is one of the most important avenues of the future to develop new antibiotics , vaccines and other treatments yet to be discovered , '' said Kean President Dawood Farahi , Ph.D. `` Institute for Life Science Entrepreneurship at Kean University 's partnership with CARB-X will allow some of these new ideas to come to fruition . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.